Business

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations

Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 monthsOther analyses broadly in line with the trends seen for Mont BlancData presentations planned for upcoming ophthalmology conferences October 2, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Gr